TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01846767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose breath test
Description: Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose breath test
Description: Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
Study: NCT02778113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT01014845

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Intramuscularly given at 0, 1, 6m for three doses.
Study: NCT03573453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Description: administration of enteral nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Description: administration of enteral nutrition
Study: NCT02276092

Intervention type: OTHER
Intervention: antimicrobial stewardship
Description: A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
Study: NCT01137240

Intervention type: PROCEDURE
Intervention: gastric emptying scan
Description: subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal.
Study: NCT02841059

Intervention type: PROCEDURE
Intervention: LSH
Description: laparoscopic subtotal hysterectomy: LSH

Intervention type: PROCEDURE
Intervention: CLSH
Description: laparoscopic cervical ligament sparing hysterectomy: CLSH

Intervention type: PROCEDURE
Intervention: LAVH
Description: laparoscopic assisted vaginal hysterectomy: LAVH
Study: NCT06147557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 14 heat sessions, during each session subjects were fully immersed in a 45°C water bath for 5 minutes.
Study: NCT04527198

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brainstem Responses Assessment Sedation Score (BRASS)
Description: It consists of a standardized evaluation of brainstem reflexes with a score of 1 attributed for absence of pupillary light reflex, cough reflex and the combined absence of grimace and oculocephalic reflex, a score of 2 for absent corneal reflex and a score of 3 for absent grimace in the presence of oculocephalic The resulting sum ranges from 0 to 7.~It will be performed at two times points: a first time under sedation and a second time 3 to 5 days after sedation weaning.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalogram with EKG lead
Description: A 20 minutes clinical (12 electrodes) EEG with an EKG lead will be performed a first time under sedation and a second time 3 to 5 days after sedation weaning.~These EEG recordings will allow to measure the sympathic-parasympathetic ratio using spectral analysis of the EKG and also to measure quantitative markers of brain EEG activity (spectral power and connectivity in delta, theta, alpha, beta and gamma band; complexity).
Study: NCT03135847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactor
Description: The tactor is a small robot providing touch and vibration.
Study: NCT02847754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric resistance training
Description: Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band
Study: NCT01980472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab, carboplatin and paclitaxel
Description: 4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
Study: NCT01385020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil & red yeast rice (LipoCol)
Description: The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
Study: NCT00521521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT00122135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Values Inventory (VI)
Description: The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
Study: NCT02396732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily dose is 81 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
Study: NCT01894204

Intervention type: OTHER
Group type: OTHER
Intervention: HTPPE
Description: No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
Study: NCT03484468

Intervention type: DEVICE
Intervention: anterior segment Ocular Coherence Tomography
Description: anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.

Intervention type: DEVICE
Intervention: anterior segment Ocular Coherence Tomography
Description: anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
Study: NCT02778113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study: NCT02264587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Description: Mosapride 5mg by mouth ,3 times one day for 1 4days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: domperidone
Description: Domperidone 10mg by mouth ,3 times one day for 1 4days.
Study: NCT00697671

Intervention type: OTHER
Group type: OTHER
Intervention: NK Cell Infusion
Description: All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
Study: NCT02778113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Administered SC.
Study: NCT04500561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Yy-20394 combined with Gemcitabine and Oxaliplatin was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of Gemcitabine and Oxaliplatin was treated according to clinical standards.
Study: NCT03370159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03472560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: IV treatment: Avelumab administered at 800 mg IV every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Oral treatment: Axitinib given 5 mg PO BID
Study: NCT00485888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipralex
Description: 10-20mg; one per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched to Cipralex
Study: NCT01534676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: A routine medical procedure to transfuse packed red blood cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood
Description: Processing of RBC for transfusion include the following:~* Fresh~* Stored~* Washed~* Frozen (Cryopreserved)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chelation therapy
Description: (non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Description: (non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
Study: NCT00305656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study: NCT01533675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Once daily topical application of normal saline, using a cotton-tipped applicator
Study: NCT04204174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tyrosine, brand name: myprotein
Description: tyrosine at a dose of 100 mg/kg is then administered orally to the participants once
Study: NCT01777152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
Study: NCT03542396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPuls
Description: Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
Study: NCT01764919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: A single intravenous injection of 5 mCi\[124I\]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
Study: NCT00294619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: subcutaneous injection, once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: growth hormone
Description: subcutaneous injection, once-weekly
Study: NCT00922727

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: The oil drops contains 10\^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10\^8 CFU/ 5 drops and less than 8 x 10\^8 CFU/ 5 drops.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Description: As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10\^8 CFU/ 5 drops.
Study: NCT01777152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Study: NCT04408560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules)
Description: Rhus toxicodendron 9 CH + Ruta graveolens 5 CH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol (drug analgesic class1)
Description: paracetamol (drug analgesic class1)
Study: NCT01777152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Study: NCT04408560

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: paracetamol (drug analgesic class1)
Description: paracetamol (drug analgesic class1)
Study: NCT02925949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DuoPACT
Description: 6 couple-based intervention sessions are administered weekly by a counselor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LifeSteps
Description: 3 individual-based intervention sessions are administered weekly by a counselor.
Study: NCT04152564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine infusion via Thoracic epidural catheter
Description: The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine infusion via preperitoneal catheter
Description: At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
Study: NCT00271505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: 15 mg/kg intravenously (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV every 3 weeks
Study: NCT04189185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture fixation
Description: The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture fixation
Description: The fracture is reduced. A 2.5 mm hole is drilled in the dorsal olecranon 15mm from the fracture. A suture is passed through the hole and is fixed to the triceps muscle. A second suture is fixed to the triceps muscle in a figure 8 configuration.
Study: NCT01537614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIMYCINE inhalation
Description: 2 MILLION UI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIMYCINE injectable
Description: 2 MILLIONS UI
Study: NCT02345564

Intervention type: DEVICE
Group type: OTHER
Intervention: implantation of MaioRegen fleece into osteochondral lesion
Description: arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
Study: NCT04849702

Intervention type: PROCEDURE
Intervention: No intervention was compared
Description: No intervention was compared
Study: NCT01893034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic treatment of femoroacetabular impingement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and activity modification
Study: NCT01777152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
Study: NCT00625664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: administered on day 1 as a 1-hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: administered on day 1, 8 and 15 as a 30-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 1 hour infusion administered on day 1, 30 minutes after the other treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 1 hour infusion administered on day 1, 30 minutes after the other treatment
Study: NCT02215980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02526030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study: NCT02937402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with Bronchoalveolar Lavage
Description: Undergo bronchoscopy with bronchoalveolar lavage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Laboratory Biomarker Analysis
Study: NCT00508664

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation start in week 11

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation start in week 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 i.v. day 1 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 i.v. day 1 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (TP)
Description: 75 mg/m2 i.v. day 1 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (TP)
Description: 75 mg/m2 i.v. day 1 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (TPF) (only until Feb 2009)
Description: Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (TPF) (only until Feb 2009)
Description: Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
Study: NCT04628455

Intervention type: DEVICE
Group type: OTHER
Intervention: Inversion and snaring
Description: Vertical umbilical 5-mm incision was made for 5-mm trocar. Pneumoperitoneum is then established with CO2 flow of 1.5-2.5 L/min keeping intraabdominal pressure between 8-12 mmHg. A two-mm incision was done at a point B \[midway between umbilicus and symphysis pubis\] for 2-mm port passed under direct vision and a tiny 11-blade scalpel puncture is done at the corresponding Mac-Burney's \[Point C\] for SGD.~Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. Then, the MPS is introduced via 2-mm trocar at point. SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS was closed at the neck and diathermy current is applied. Detached sac was then pushed antigradely out through the umbilical port.
Study: NCT02290743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.